Our Recent Posts


No tags yet.

The Daily Scan

Last Updated: 1:00 PM EST


  • The American Medical Association (AMA) recently launched a newly enhanced version of its Health Workforce Mapper with updated data to further help physicians and other health care providers improve patient access to care. In addition to illustrating the geographic locations of the health care work force in each state, including physician specialties and sub-specialties, the tool provides population health data by geographic location. The “Population Health Explorer” feature offers data on a variety of population health factors, including health care access and quality, health behaviors such as smoking and alcohol use, demographics, and social environment factors. This feature enables users to not only see where the physicians of the country practice, but overlay where the patients are located, and the factors that influence their health and access to care. Specifically, the AMA’s Health Workforce Mapper tool gives physicians and other health care providers information—using reliable AMA data as well as data from the Centers for Disease Control and Prevention and Centers for Medicare and Medicaid Services—to identify health professional shortage areas, hospital locations, as well as other related workforce trends. (AMA-Assn.org)

  • The Centers for Medicare & Medicaid Services (CMS) has developed a Market Saturation and Utilization Data Tool that includes interactive maps and a dataset that shows national-, state-, and county-level provider services and utilization data for selected health service areas. Market saturation, in the present context, refers to the density of providers of a particular service within a defined geographic area relative to the number of the beneficiaries receiving that service in the area. The Market Saturation and Utilization Data Tool is one of many tools used by CMS to monitor and manage market saturation as a means to help prevent potential fraud, waste, and abuse. The data can also be used to reveal the degree to which use of a service is related to the number of providers servicing a geographic region. (CMS.gov)


  • Last week, the FDA approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.“ This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years. The safety and efficacy of Xofluza, an antiviral drug taken as a single oral dose, was demonstrated in two randomized controlled clinical trials of 1,832 patients where participants were assigned to receive either Xofluza, a placebo, or another antiviral flu treatment within 48 hours of experiencing flu symptoms. In both trials, patients treated with Xofluza had a shorter time to alleviation of symptoms compared with patients who took the placebo. In the second trial, there was no difference in the time to alleviation of symptoms between subjects who received Xofluza and those who received the other flu treatment. (FDA.gov)


  • Judge Paul S. Diamond of the United States District Court for the Eastern District of Pennsylvania issued a memorandum yesterday dismissing an Administrative Procedure Act (APA) claim in the case of Endo Pharmaceuticals et al. v. Federal Trade Commission: "After the Federal Trade Commission voluntarily dismissed its enforcement action in this Court against Plaintiffs Watson Laboratories and Allergan Finance—and then refiled that same enforcement action in California—Plaintiffs brought this declaratory judgment suit, repeating the arguments made in their motions to dismiss in the original enforcement action. Although the FTC’s apparent forum shopping may warrant sanctions, the law does not allow Plaintiffs to challenge the Commission’s enforcement decisions by way of declaratory judgment when they can do so in defending against the California enforcement action itself. Accordingly, I will grant the FTC’s Motion to Dismiss." (CourtListener.com)

#Litigation #Regulation #Research


1 PPG Place, 31st Floor,

Pittsburgh, PA 15222

©2018 by FHAS Inc.